Twenty years after opening, the H. Lee Moffitt Cancer Center &Research Institute is submitting its second competitive renewal application for its Cancer Center Support Grant for grant years 10 through 14. The Center's mission remains solely focused on """"""""contributing to the prevention and cure of cancer."""""""" The Moffitt Cancer Center, a freestanding, not-for-profit corporation located on the University of South Florida campus in Tampa, Florida, includes a research institute coupled with a 162-bed inpatient facility, an active outpatient clinic with more than 200,000 patient visits per year, a high-risk screening and prevention center, a dedicated Clinical Research Unit for early phase studies, an affiliate network of Florida hospitals and oncology practices and a wide array of outreach and educational activities. The Cancer Center has five scientific programs, all with a translational focus;14 shared resources (five newly proposed), and a research infrastructure that supports innovative, translational research and enhances interactions among basic scientists, population-based scientists and clinical investigators. Research programs include Molecular Oncology &Drug Discovery, Immunology, Experimental Therapeutics, Risk Assessment, Detection &Intervention, and Health Outcomes &Behavior. Shared resources include Flow Cytometry, Molecular Biology, Microarray, Proteomics, High Throughput Screening &Chemistry, Mouse Models, Analytic Microscopy, Tissue, Cell Therapies, Survey Methods, Informatics, Biostatistics, Clinical Research Support Services and the Clinical Trials Laboratory Core. The Protocol Review &Monitoring System includes two Scientific Review Committees and a separate Protocol Monitoring Committee. Protocol specific support for a large-volume early phase clinical trial portfolio is also requested. During the period since designation as an NCI Comprehensive Cancer Center and the current CCSG submission (2001-2006), the Center has more than doubled its peer reviewed funding and increased NCI funding from $10.6 million to $29 million total dollars;increased accrual to phase I investigator-authored clinical trials from 130 to 534 annually and enrollment on all trials to more than 6,000;opened the Stabile Research Building to nearly double available research space;and created a network of 16 affiliate hospitals and 380 physicians throughout Florida. The Center's 135 members collaborate extensively with 25% of total publications being inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA076292-13S1
Application #
8213876
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1998-02-18
Project End
2012-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
13
Fiscal Year
2011
Total Cost
$120,015
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Karolak, Aleksandra; Rejniak, Katarzyna A (2018) Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. Bull Math Biol :
Karolak, Aleksandra; Estrella, Veronica C; Huynh, Amanda S et al. (2018) Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling. Sci Rep 8:3638
Barata, Anna; Gonzalez, Brian D; Sutton, Steven K et al. (2018) Coping strategies modify risk of depression associated with hematopoietic cell transplant symptomatology. J Health Psychol 23:1028-1037
Li, Qian; Balagurunathan, Yoganand; Liu, Ying et al. (2018) Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial. Clin Lung Cancer 19:148-156.e3
Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua et al. (2018) GSK3 suppression upregulates ?-catenin and c-Myc to abrogate KRas-dependent tumors. Nat Commun 9:5154
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Ctortecka, Claudia; Palve, Vinayak; Kuenzi, Brent M et al. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics 17:2434-2447
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Schmit, Stephanie L; Edlund, Christopher K; Schumacher, Fredrick R et al. (2018) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst :
Kang, Sokbom; Thompson, Zachary; McClung, E Claire et al. (2018) Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. Int J Gynecol Cancer 28:260-266

Showing the most recent 10 out of 1254 publications